FDA Seeks Industry Representatives for Advisory Committee Roles
Posted 07 February 2019 | By
The US Food and Drug Administration (FDA) on Thursday issued a call for nominations for nonvoting industry representatives to serve on 17 of the Center for Drug Evaluation and Research’s (CDER) public advisory committees.
The agency is also calling for industry groups to participate in the selection process.
FDA advisory committees include four types of members, scientific and medical experts in the area of medicine or the scientific/technical field the committee covers, as well as a consumer, patient and industry representative.
Industry representatives are charged with acting on the behalf of the regulated industry, but do not represent specific companies and do not vote on matters before the committees.
FDA is looking to add an industry representative to the following committees:
- Anesthetic and Analgesic Drug Products Advisory Committee
- Antimicrobial Drugs Advisory Committee
- Arthritis Advisory Committee
- Bone, Reproductive, and Urologic Drugs Advisory Committee
- Cardiovascular and Renal Drugs Advisory Committee
- Dermatologic and Ophthalmic Drugs Advisory Committee
- Drug Safety and Risk Management Advisory Committee
- Endocrinologic and Metabolic Drugs Advisory Committee
- Gastrointestinal Drugs Advisory Committee
- Medical Imaging Drugs Advisory Committee
- Nonprescription Drugs Advisory Committee
- Oncologic Drugs Advisory Committee
- Peripheral and Central Nervous System Drugs Advisory Committee
- Pharmaceutical Science and Clinical Pharmacology Advisory Committee
- Pharmacy Compounding Advisory Committee
- Psychopharmacologic Drugs Advisory Committee
- Pulmonary-Allergy Drugs Advisory Committee
The agency is asking for nominations for the nonvoting industry representative positions to be submitted within 30 days. Selected members will serve a four-year term beginning 1 November 2019.
Industry organizations interested in participating in the selection process are instructed to send a letter of intent to FDA within 30 days. Afterwards FDA will forward the list of nominees to those organizations, who will be tasked with selecting nominees within 60 days. If a representative for a committee is not selected within that time the FDA Commissioner is charged with making the selection.
Federal Register Notice